Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 16/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MC4R | P32245 | 1/20 | 0.51 |
| ▸ | MC5R | P33032 | 1/20 | 0.51 |
| ▸ | MC3R | P41968 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11224818 | 0.85 | ALDH1A1 (0.59) | TPSAB1ALDH1A1MC4R | |
| SCHEMBL4398574 | 0.84 | ALDH1A1 (0.51) | TPSAB1ALDH1A1 | |
| SCHEMBL11233209 | 0.84 | ALDH1A1 (0.71) | ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4410347 | 0.83 | TPSAB1 (1.00) | TPSAB1 | |
| SCHEMBL11258267 | 0.82 | ALDH1A1 (0.62) | ALDH1A1 | |
| SCHEMBL11240160 | 0.79 | ALDH1A1 (0.66) | ALDH1A1 | |
| SCHEMBL11331493 | 0.78 | ALDH1A1 (0.53) | TPSAB1ALDH1A1MC4R | |
| SCHEMBL11349537 | 0.77 | MPO (0.56) | ALDH1A1 | |
| SCHEMBL11240204 | 0.77 | ALDH1A1 (0.66) | ALDH1A1 | |
| SCHEMBL11309055 | 0.77 | ALDH1A1 (0.66) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296972-B1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-12-23 | — | — | EP | disclosed |
| US-6977263-B2 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050228018-A1 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20030187020-A1 | Chemical compounds | AVENTISUB LLC | 2003-10-02 | — | — | US | disclosed |
| EP-1296972-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001090101-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228018-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | TPSAB1 4/4885ALDH1A1 729/4885MC4R 1102/4885 |
| US-20030187020-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | TPSAB1 4/4885ALDH1A1 729/4885MC4R 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.